Eloxx Pharmaceuticals announced that Robert (“Bob”) Ward has been appointed chairman of the board of directors of Eloxx, and chief executive officer. Bob joins at a critical inflection point for Eloxx as the company advances its Lead candidate ELX-02, a novel translational read-through inducing drug (TRID), through the completion of Phase 1 Clinical Trials and navigates its transition from a private to a public company.
Mr. Ward comes with more than 30 years of experience as a global Biopharmaceutical industry leader with experience across the full spectrum of drug development, commercialization, and strategic business development transactions. He most recently was the president and chief executive officer of Radius Health, Inc.
"We are pleased to have attracted an experienced leader with Bob’s proven track record of success to Eloxx,” said Dr. Robert Heft. “Having previously lead a fully integrated commercial biopharmaceutical company to achieve its first drug approval and product launch, we are confident that Bob is the right leader to advance Eloxx as we seek to develop and commercialize our novel small molecule medicines to treat rare and ultra-rare genetic diseases.”
